| Literature DB >> 34944604 |
Gennady A Badun1, Maria G Chernysheva1, Yury V Zhernov1,2, Alina S Poroshina3, Valery V Smirnov2,3, Sergey E Pigarev4,5, Tatiana A Mikhnevich1, Dmitry S Volkov1,6, Irina V Perminova1, Elena I Fedoros4,5.
Abstract
Natural products (e.g., polyphenols) have been used as biologically active compounds for centuries. Still, the mechanisms of biological activity of these multicomponent systems are poorly understood due to a lack of appropriate experimental techniques. The method of tritium thermal bombardment allows for non-selective labeling and tracking of all components of complex natural systems. In this study, we applied it to label two well-characterized polyphenolic compounds, peat fulvic acid (FA-Vi18) and oxidized lignin derivative (BP-Cx-1), of predominantly hydrophilic and hydrophobic character, respectively. The identity of the labeled samples was confirmed using size exclusion chromatography. Using ultra-high resolution Fourier transform ion cyclotron resonance mass spectrometry (FT ICR MS), key differences in the molecular composition of BP-Cx-1 and FA-Vi18 were revealed. The labeled samples ([3H]-FA-Vi18 (10 mg/kg) and [3H]-BP-Cx-1 (100 mg/kg)) were administered to female BALB/c mice intravenously (i.v.) and orally. The label distribution was assessed in blood, liver, kidneys, brain, spleen, thymus, ovaries, and heart using liquid scintillation counting. Tritium label was found in all organs studied at different concentrations. For the fulvic acid sample, the largest accumulation was observed in the kidney (Cmax 28.5 mg/kg and 5.6 mg/kg, respectively) for both routes. The organs of preferential accumulation of the lignin derivative were the liver (Cmax accounted for 396.7 and 16.13 mg/kg for i.v. and p.o. routes, respectively) and kidney (Cmax accounted for 343.3 and 17.73 mg/kg for i.v. and p.o. routes, respectively). Our results demonstrate that using the tritium labeling technique enabled successful pharmacokinetic studies on polyphenolic drugs with very different molecular compositions. It proved to be efficient for tissue distribution studies. It was also shown that the dosage of the polyphenolic drug might be lower than 10 mg/kg due to the sensitivity of the 3H detection technique.Entities:
Keywords: fulvic acid; intravenous; lignin; oral; pharmacokinetics; polyphenolic composition; tissue distribution; tritium label
Year: 2021 PMID: 34944604 PMCID: PMC8698565 DOI: 10.3390/biomedicines9121787
Source DB: PubMed Journal: Biomedicines ISSN: 2227-9059
Elemental composition of the fulvic acid and of the lignin-derived substance samples under study (on an ash-free basis).
| Sample | C% | H% | N% | O% | O/C | H/C |
|---|---|---|---|---|---|---|
| Fulvic acid (FA-Vi18) | 49.14 | 5.19 | 1.29 | 44.38 | 0.68 | 1.27 |
| Lignin derivative (BP-Cx-1) | 65.60 | 4.11 | 0.00 | 30.29 | 0.35 | 0.75 |
Distribution of carbon among the major structural groups in the studied fulvic acid and BP-Cx-1 samples (% of total C atoms by the 13C NMR data).
| Sample | CHn | CH3O | CalkO | Car | CarO | COO | C = O | ΣCar | ΣCar/ΣCalk |
|---|---|---|---|---|---|---|---|---|---|
| FA-Vi18 | 28 | 5 | 12 | 22 | 8 | 20 | 5 | 30 | 0.67 |
| BP-Cx-1 | 20 | 5 | 11 | 39 | 8 | 11 | 7 | 47 | 1.3 |
Figure 1Van Krevelen diagrams of the (a) BP-Cx-1, (b) FA-Vi18, (c) unique formulae for BP-Cx-1 (green) and for FA-Vi18 (red), and (d) common formulas both BP-Cx-1 and FA-Vi18 (brown). The dot size corresponds to the peak intensity in the mass list. On van Krevelen diagrams of all assigned formulas (a,b), CHO formulae are highlighted in blue, and CHON in yellow.
Figure 2Occupational densities on van Krevelen diagram of each chemotype (condensed tannins, phenylisopropanoids, terpenoids, lipids, proteins, carbohydrates, hydrolyzed tannins) for BP-Cx-1 (green) and FA-Vi18 (orange), which were calculated according to Perminova [43].
Figure 3UV and radioactivity profiles of (a) tritium-labeled BP-Cx-1 and (b) tritium-labeled FA-Vi18. Ar is radioactivity normalized per total eluted radioactivity, OD is optical density. Radioactivity profile is highlighted in orange and its appropriate scale is indicated with a left-oriented-arrow, UV-profile is highlighted in blue, and its appropriate scale is indicated with a right-oriented arrow.
The main pharmacokinetic parameters after intravenous injection of [3H]-FA-Vi18 at 10 mg/kg to female BALB/c mice (n = 3).
| Index | Organ or Tissue | |||||||
|---|---|---|---|---|---|---|---|---|
| Blood | Liver | Kidneys | Brain | Spleen | Thymus | Ovaries | Heart | |
| Cmax, mg/kg | 14.12 | 9.65 | 28.53 | 0.69 | 3.60 | 2.57 | 4.14 | 6.06 |
| Tissue-to-blood ratio | 1.00 | 0.68 | 2.02 | 0.05 | 0.25 | 0.18 | 0.29 | 0.43 |
| Tmax, min | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| AUC0-24 h × mg × kg−1 | 27.79 | 45.08 | 250.86 | 9.36 | 23.94 | 12.07 | 13.62 | 18.75 |
| Lz, min−1 × kg−1 | 0.059 | 0.013 | 0.013 | 0.014 | 0.016 | 0.040 | 0.038 | 0.036 |
| AUC0-inf, h × mg × kg−1 | 34.6 | 164.2 | 884.9 | 31.9 | 71.8 | 19.6 | 21.6 | 31.2 |
| T1/2, h | 11.7 | 53.7 | 52.2 | 48.0 | 42.0 | 17.4 | 18.4 | 19.7 |
| MRT, h | 12.6 | 76.4 | 74.1 | 69.0 | 59.7 | 24.0 | 23.6 | 25.7 |
Figure 4Distribution profiles resulting from Log2 scale transformation of the tissue concentrations of FA-Vi18 sample and the lignin derivative BP-Cx-1 administered to female BALB/c mice. The radar profiles of planes (a) and (c) correspond to single intravenous injection, and planes (b) and (d) correspond to single gavage administration of [3H]-labeled FA-Vi18 (10 mg/kg) and BP-Cx-1 (100 mg/kg), respectively.
The main pharmacokinetic parameters after gavage administration of [3H]-FA-Vi18 at 10 mg/kg to female BALB/c mice (n = 3).
| Index | Organ or Tissue | |||||||
|---|---|---|---|---|---|---|---|---|
| Blood | Liver | Kidneys | Brain | Spleen | Thymus | Ovaries | Heart | |
| Cmax, mg/kg | 1.99 | 2.02 | 5.6 | 0.51 | 0.64 | 1.37 | 0.34 | 0.86 |
| Tissue-to-blood ratio | 1.00 | 1.01 | 2.8 | 0.25 | 0.32 | 0.69 | 0.17 | 0.43 |
| Tmax, min | 30 | 30 | 30 | 120 | 30 | 60 | 30 | 30 |
| AUC0-48 h × mg × kg−1 | 18.15 | 24.11 | 25.32 | 15.46 | 16.84 | 13.13 | 1.72 | 789 |
| Lz, h−1 × kg−1 | 0.017 | 0.015 | 0.014 | 0.011 | 0.010 | 0.007 | - | 0.0001 |
| AUC0-inf, h × mg ×kg−1 | 33.3 | 45.2 | 54.0 | 38.2 | 45.4 | 48.6 | - | 47.7 |
| T1/2, h | 41.0 | 44.9 | 50.9 | 60.6 | 66.9 | 96.8 | - | 88.7 |
| MRT, h | 59.3 | 63.7 | 73.4 | 89.1 | 98.8 | 142.9 | - | 133.5 |
The main pharmacokinetic parameters after intravenous injection of [3H]-BP-Cx-1 at 100 mg/kg to female BALB/c mice (n = 3).
| Index | Organ or Tissue | |||||||
|---|---|---|---|---|---|---|---|---|
| Blood | Liver | Kidneys | Brain | Spleen | Thymus | Ovaries | Heart | |
| Cmax, mg/kg | 155.2 | 396.7 | 343.3 | 6.3 | 233.3 | 28.2 | 115.7 | 5.4 |
| Tissue-to-blood ratio | 1.00 | 2.56 | 2.21 | 0.04 | 1.50 | 0.18 | 0.75 | 0.03 |
| Tmax, min | 360 | 5 | 120 | 360 | 5 | 60 | 720 | 5 |
| AUC0-12 h × mg × kg−1 | 1297.6 | 2650.0 | 3134.2 | 64.9 | 756.6 | 300.4 | 808.2 | 53.0 |
| Lz, h−1 × kg−1 | 0.102 | 0.047 | - | 0.045 | 0.063 | - | - | - |
| AUC0-inf, h × mg × kg−1 | 2138.3 | 6242.5 | - | 173.9 | 1649.0 | - | - | - |
| T1/2, h | 6.8 | 14.6 | - | 15.5 | 10.9 | - | - | - |
| MRT, h | 15.5 | - | - | 64.7 | 11.5 | - | - | - |
The main pharmacokinetic parameters after gavage administration of [3H]-BP-Cx-1 at 100 mg/kg to female BALB/c mice (n = 3).
| Index | Organ or Tissue | |||||||
|---|---|---|---|---|---|---|---|---|
| Blood | Liver | Kidneys | Brain | Spleen | Thymus | Ovaries | Heart | |
| Cmax, mg/kg | 2.70 | 16.13 | 17.73 | 2.10 | 4.33 | 7.33 | 1.17 | 0.16 |
| Tissue-to-blood ratio | 1.00 | 5.98 | 6.57 | 0.78 | 1.60 | 2.72 | 0.43 | 0.06 |
| Tmax, min | 120 | 120 | 120 | 30 | 120 | 120 | 360 | 120 |
| AUC0-48 h × mg × kg−1 | 73.1 | 275.4 | 227.7 | 58.3 | 74.7 | 76.0 | 36.4 | 2.9 |
| Lz, h−1 × kg−1 | 0.007 | - | 0.003 | 0.012 | 0.010 | 0.015 | - | 0.005 |
| AUC0-inf, h × mg × kg−1 | 248.5 | - | 1536.6 | 136.4 | 193.5 | 135.4 | - | 15.9 |
| T1/2, h | 91.2 | - | 226.8 | 55.9 | 68.6 | 44.1 | - | 150.5 |
| MRT, h | 133.1 | - | 322.6 | 82.6 | 97.8 | 58.4 | - | 221.1 |